The latest news, announcements and press releases from uBriGene.
Germantown, MD - March 30, 2026 - uBriGene Biosciences (uBriGene), a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) development, today announced a strategic partnership with Cellinfinity BIO, a biotechnology company developing in vivo CAR-T therapies targeting hematologic and solid tumors.
This strategic partnership will accelerate the clinical advancement of Cellinfinity BIO’s therapeutic programs CIB-301 and CIB-350. uBriGene will leverage its high-productivity LVV Turbo™ platform to deliver efficient, cost-effective GMP lentiviral vector manufacturing, including process development, GMP production, and regulatory support.
Location will produce cell and gene therapies and provide contract analytical services.
This is the News section of the company profile page for uBriGene on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
